|
Status |
Public on Aug 31, 2022 |
Title |
Patient_57 SAMPLE_57 |
Sample type |
RNA |
|
|
Source name |
Primary Skin melanoma
|
Organism |
Homo sapiens |
Characteristics |
tissue: Primary Skin melanoma histology: Superficial spreading melanoma status after 5 years: dead age: 62 Sex: woman status: brisk braf v600e ihc status: positive Stage: 2
|
Extracted molecule |
total RNA |
Extraction protocol |
Total RNA was isolated from five 10-µm sections of whole FFPE tissue using Roche hi-pure FFPET kit (Roche Life Science, Mannheim, Germany) according to manufacturer`s protocol. NanoDrop™ Lite spectrophotometer (Thermo Fischer Scientific, Waltham, Massachusetts, US) was used to measure total RNA quality and quantity.
|
Label |
biotin
|
Label protocol |
biotinylated capture probe was used to pair withthe targit probe
|
|
|
Hybridization protocol |
From each sample, 100-200 ng of RNA was used for hybridization using the nCounter PanCancer IO 360 Gene Expression Panel, according to the manufacturer’s nCounter XT protocol (NanoString Technologies, Seattle, Washington, US).
|
Scan protocol |
digitl detection and counting of the hybridized probes wer done one an epifluorescence microscope in the digital analyzer mode, NanoString Technologies, Seattle, Washington, US
|
Description |
raw data were quality checked in the nSolver software by using default parameters, imaging QC, bibdng density, positive control linearity and positive control limit detection (set to 0.5 fM) was evaluated
|
Data processing |
Data analysis was performed in nSover software version 4.0
|
|
|
Submission date |
Jan 17, 2022 |
Last update date |
Aug 31, 2022 |
Contact name |
Soraya Naimy |
E-mail(s) |
sona@regionsjaelland.dk
|
Organization name |
zealand universityhospital
|
Department |
department of pathology
|
Street address |
sygehusvej 9
|
City |
roskilde |
State/province |
Sjaelland |
ZIP/Postal code |
4000 |
Country |
Denmark |
|
|
Platform ID |
GPL31236 |
Series (1) |
GSE193802 |
Gene expression related to tumor infiltrating lymphocytes status and BRAFV600E status in naive melanoma cancer patients |
|